
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2003

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

Commission file number 000-32085

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

36-4392754

(I.R.S. Employer
Identification Number)

2401 Commerce Drive

Libertyville, Illinois 60048

(Address of principal executive offices)

(847) 680-3515

(Registrant's telephone number, including area code)

Indicate by check (X) whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark (X) whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of October 31, 2003, there were 38,931,558 shares of the registrant's \$0.01 par value common stock outstanding.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
FORM 10-Q
INDEX

[PART I. FINANCIAL INFORMATION](#)

[Item 1. Financial Statements](#)

[Consolidated Balance Sheets at September 30, 2003 and December 31, 2002](#)

[Consolidated Statements of Operations for the three and nine months ended September 30, 2003 and 2002](#)

[Consolidated Statements of Cash Flows for the nine months ended September 30, 2003 and 2002](#)

[Notes to Consolidated Financial Statements](#)

[Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](#)

[Item 3. Quantitative and Qualitative Disclosures About Market Risk](#)

[Item 4. Controls and Procedures](#)

[PART II. OTHER INFORMATION](#)

[Item 6. Exhibits and Reports on Form 8-K](#)

[SIGNATURES](#)

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except per-share amounts)

| | <u>September 30,</u> <u>2003</u> | <u>December 31,</u> <u>2002</u> |
|---|-------------------------------------|------------------------------------|
| | <u>(Unaudited)</u> | |
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 10,496 | \$ 17,247 |
| Marketable securities | 5,698 | 19,117 |
| Accounts receivable, net of allowances of \$3,626 at September 30, 2003 and \$3,876 at December 31, 2002 | 15,796 | 18,659 |
| Other receivables | 369 | 747 |
| Inventories | 3,244 | 3,988 |
| Prepaid expenses | 3,448 | 2,860 |
| Other current assets | 887 | 477 |
| Total current assets | 39,938 | 63,095 |
| Long-term marketable securities | 36,004 | 28,922 |
| Fixed assets, net | 2,566 | 4,384 |
| Software development costs, net | 3,070 | 2,676 |
| Intangible assets, net | 11,971 | 4,060 |
| Goodwill | 14,705 | 733 |
| Other assets | 488 | 483 |
| Total assets | \$ 108,742 | \$ 104,353 |
| Liabilities and Stockholders' Equity | | |
| Current liabilities: | | |
| Accounts payable | \$ 7,022 | \$ 4,488 |
| Accrued expenses | 5,227 | 3,583 |
| Accrued compensation | 1,965 | 2,611 |
| Accrued restructuring and other charges | 180 | 1,140 |
| Deferred revenue | 9,245 | 6,547 |
| Total current liabilities | 23,639 | 18,369 |
| Other non-current liabilities | 2,042 | 163 |
| Total liabilities | 25,681 | 18,532 |
| Preferred stock: | | |
| Undesignated, \$0.01 par value, 1,000 shares authorized, no shares issued and outstanding at September 30, 2003 and December 31, 2002 | — | — |
| Common stock: | | |
| \$ 0.01 par value, 150,000 shares authorized; 38,749 shares issued and outstanding at September 30, 2003; 38,427 shares issued and outstanding at December 31, 2002 | 387 | 385 |
| Additional paid-in capital | 641,280 | 638,694 |
| Unearned compensation | — | (78) |
| Accumulated deficit | (558,634) | (553,539) |
| Accumulated other comprehensive income | 28 | 359 |
| Total stockholders' equity | 83,061 | 85,821 |
| Total liabilities and stockholders' equity | \$ 108,742 | \$ 104,353 |

The accompanying notes are an integral part of these consolidated financial statements.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per-share amounts)

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|--|-------------------------------------|-------------------|------------------------------------|--------------------|
| | 2003 | 2002 | 2003 | 2002 |
| | (Unaudited) | | | |
| Revenue: | | | | |
| Prepackaged medications | \$ 10,990 | \$ 12,799 | \$ 34,278 | \$ 37,758 |
| Software and related services | 8,232 | 4,819 | 20,048 | 14,276 |
| Information services | 3,266 | 2,388 | 7,862 | 6,839 |
| Total revenue | <u>22,488</u> | <u>20,006</u> | <u>62,188</u> | <u>58,873</u> |
| Cost of revenue: | | | | |
| Prepackaged medications | 8,690 | 10,257 | 26,843 | 30,587 |
| Software and related services | 3,827 | 3,418 | 10,786 | 11,497 |
| Information services | 1,316 | 1,095 | 3,199 | 2,761 |
| Total cost of revenue | <u>13,833</u> | <u>14,770</u> | <u>40,828</u> | <u>44,845</u> |
| Gross profit | 8,655 | 5,236 | 21,360 | 14,028 |
| Selling, general and administrative expenses | 9,618 | 8,314 | 26,974 | 28,316 |
| Amortization of intangible assets | 295 | 135 | 563 | 407 |
| Restructuring and other charges | — | 600 | — | 600 |
| Loss from operations | <u>(1,258)</u> | <u>(3,813)</u> | <u>(6,177)</u> | <u>(15,295)</u> |
| Interest and other income, net | 340 | 614 | 1,082 | 2,110 |
| Loss before income taxes | <u>(918)</u> | <u>(3,199)</u> | <u>(5,095)</u> | <u>(13,185)</u> |
| Provision for income tax | — | — | — | — |
| Net loss | <u>\$ (918)</u> | <u>\$ (3,199)</u> | <u>\$ (5,095)</u> | <u>\$ (13,185)</u> |
| Net loss per share—basic and diluted | <u>\$ (0.02)</u> | <u>\$ (0.08)</u> | <u>\$ (0.13)</u> | <u>\$ (0.34)</u> |
| Weighted-average shares of common stock outstanding used in computing net loss per share—basic and diluted | <u>38,628</u> | <u>38,424</u> | <u>38,509</u> | <u>38,308</u> |

The accompanying notes are an integral part of these consolidated financial statements.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

| | Nine Months Ended September 30, | |
|---|------------------------------------|------------------|
| | 2003 | 2002 |
| (Unaudited) | | |
| Cash flows from operating activities: | | |
| Net loss | \$ (5,095) | \$ (13,185) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | | |
| Depreciation and amortization | 3,831 | 4,386 |
| Restructuring and other charges | — | 600 |
| Non-cash compensation expense | 78 | 244 |
| Realized gain on investments | (29) | (98) |
| Provision for doubtful accounts | 420 | 761 |
| Changes in assets and liabilities, net of effects of acquisitions: | | |
| Accounts receivable | 3,412 | (3,829) |
| Other receivables | 378 | (432) |
| Inventories | 706 | 2,513 |
| Prepaid expenses and other current and non-current assets | (29) | (287) |
| Accounts payable | 2,241 | (45) |
| Accrued expenses | 132 | (442) |
| Accrued compensation | (1,040) | 51 |
| Accrued restructuring and other charges | (960) | (1,512) |
| Deferred revenue | (209) | 598 |
| Other non-current liabilities | 50 | 10 |
| Net cash provided by (used in) operating activities | <u>3,886</u> | <u>(10,667)</u> |
| Cash flows from investing activities: | | |
| Capital expenditures | (525) | (1,681) |
| Purchase of marketable securities | (38,049) | (27,975) |
| Maturities of marketable securities | 44,084 | 24,639 |
| Payments for acquisitions, net of cash acquired | (14,977) | — |
| Capitalized software and website development costs | (1,205) | (1,813) |
| Net cash used in investing activities | <u>(10,672)</u> | <u>(6,830)</u> |
| Cash flows from financing activities: | | |
| Payments of capital lease obligations | (200) | (163) |
| Proceeds from issuance of common stock, net of transaction costs | 235 | 2,007 |
| Net cash provided by financing activities | <u>35</u> | <u>1,844</u> |
| Net decrease in cash and cash equivalents | (6,751) | (15,653) |
| Cash and cash equivalents, beginning of period | 17,247 | 34,124 |
| Cash and cash equivalents, end of period | <u>\$ 10,496</u> | <u>\$ 18,471</u> |
| Supplemental disclosure of cash flow information: | | |
| Cash paid during the period for interest | \$ 21 | \$ 38 |

The accompanying notes are an integral part of these consolidated financial statements.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited, dollar and share amounts in thousands, except per-share amounts)

1. Basis of Presentation

The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries (collectively referred to as "Allscripts"). All significant intercompany accounts and transactions have been eliminated in consolidation. The quarterly financial information presented herein should be read in conjunction with Allscripts' audited consolidated financial statements and the accompanying notes included in our Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on a basis consistent with those consolidated financial statements and reflect all adjustments (all of which are of a normal recurring nature) that are, in the opinion of management, necessary for a fair presentation of the results for the interim periods. The consolidated balance sheet as of December 31, 2002, was derived from Allscripts' audited financial statements. The results for the interim periods are not necessarily indicative of the results to be expected for future quarters or the year. Certain reclassifications have been made in the prior period financial statements to conform to the current period presentation.

Stock-based compensation cost

Allscripts applies the provisions of Statement of Financial Accounting Standards (SFAS) No. 123, "Accounting for Stock-Based Compensation." As allowed by SFAS No. 123, Allscripts has elected to continue to account for its stock-based compensation programs according to the provisions of Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees." Accordingly, compensation expense has been recognized based on the intrinsic value of compensatory options or shares granted under the plans.

Had Allscripts elected to apply the provisions of SFAS No. 123 regarding recognition of compensation expense to the extent of the calculated fair value of stock options granted, reported net loss and net loss per share would have been increased as follows:

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|------------|------------------------------------|-------------|
| | 2003 | 2002 | 2003 | 2002 |
| Net loss, as reported | \$ (918) | \$ (3,199) | \$ (5,095) | \$ (13,185) |
| Stock-based compensation cost included in net loss, as reported | — | 80 | 78 | 244 |
| Stock-based compensation cost | (5,213) | (4,612) | (14,340) | (14,168) |
| Pro forma net loss | \$ (6,131) | \$ (7,731) | \$ (19,357) | \$ (27,109) |
| Net loss per share-basic and diluted, as reported | \$ (0.02) | \$ (0.08) | \$ (0.13) | \$ (0.34) |
| Pro forma net loss per share—basic and diluted | \$ (0.16) | \$ (0.20) | \$ (0.50) | \$ (0.71) |

2. Business Combinations

Advanced Imaging Concepts, Inc.

On August 1, 2003, Allscripts acquired 100% of the outstanding common stock of Advanced Imaging Concepts, Inc. (AIC), a provider of document imaging, scanning and management software for the medical industry. Allscripts acquired AIC because its imaging product is rapidly becoming a critical element of Allscripts' product offering. AIC also provides potential access into the small (less than ten) physician office practice with a new product offering. AIC's results are included in Allscripts' results of operations from the date of acquisition. The purchase price of \$18,927 included the issuance of 474 common stock options in exchange for existing AIC common stock options, with a value of \$1,242, and the granting of an additional 431 common stock options, with a value of \$1,000. Common stock options granted and exchanged were valued using the Black-Scholes option-pricing model. Allscripts is in the process of obtaining a third-party valuation of an intangible asset; thus, the allocation of purchase price is subject to refinement.

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed at the date of acquisition:

| <u>Assets</u> | |
|-------------------------------|-----------|
| Cash and cash equivalents | \$ 705 |
| Accounts receivable, net | 907 |
| Other current assets | 160 |
| Fixed assets, net | 127 |
| Intangible assets | 8,389 |
| Goodwill | 10,695 |
| Other assets | 13 |
| Total assets | 20,996 |
| <u>Liabilities</u> | |
| Accounts payable | 165 |
| Accrued expenses | 181 |
| Accrued compensation | 883 |
| Deferred revenue | 811 |
| Other non-current liabilities | 29 |
| Total liabilities | 2,069 |
| Net assets acquired | \$ 18,927 |

Of the \$8,389 of acquired intangible assets, \$2,700 was assigned to registered trademarks, which are not subject to amortization. The remaining \$5,689 has a weighted-average useful life of approximately 6.6 years. The intangible assets that make up that amount include developed technology of \$3,760 (5-year weighted-average useful life), customer relationships of \$1,880 (10-year weighted-average useful life) and employment agreements of \$49 (2-year weighted-average useful life).

The \$10,695 of goodwill was assigned to the software and related services segment. Of that total amount, none is expected to be deductible for tax purposes.

RxCentric Inc.

On August 8, 2003, Allscripts acquired certain assets of RxCentric Inc. (RxCentric), a provider of technology-enabled sales and marketing solutions for the pharmaceutical industry. Allscripts acquired certain assets of RxCentric because it expanded Allscripts' client base in the United States and provided access to the international market. The results of operations related to the acquisition of certain assets of RxCentric are included in Allscripts' results of operations from the date of acquisition. The purchase price was \$1,444 in cash. Additional cash consideration of up to \$1,750 can become payable based upon the revenues of Allscripts' Physicians Interactive business in the twelve-month period following closing. Allscripts is in the process of obtaining a third-party valuation of an intangible asset and the final value of a holdback payment has not been agreed to; thus, the allocation of purchase price is subject to refinement.

The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed at the date of acquisition:

| <u>Assets</u> | |
|--------------------------|-----------------|
| Accounts receivable, net | \$ 62 |
| Other current assets | 756 |
| Fixed assets, net | 16 |
| Intangible assets | 60 |
| Goodwill | 3,281 |
| Total assets | <u>4,175</u> |
| <u>Liabilities</u> | |
| Accounts payable | 511 |
| Accrued expenses | 95 |
| Accrued compensation | 29 |
| Deferred revenue | 2,096 |
| Total liabilities | <u>2,731</u> |
| Net assets acquired | <u>\$ 1,444</u> |

The \$3,281 of goodwill was assigned to the information services segment. Of that total amount, \$3,281 is expected to be deductible for tax purposes.

The following unaudited pro forma financial information presents the combined results of operations of Allscripts, AIC and RxCentric as if the acquisitions had occurred as of January 1, 2002. The unaudited pro forma financial information is not necessarily indicative of what consolidated results of operations actually would have been had the acquisitions been completed at the dates indicated. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined company.

| | <u>Three Months Ended September 30,</u> | | <u>Nine Months Ended September 30,</u> | |
|--|---|-------------|--|-------------|
| | <u>2003</u> | <u>2002</u> | <u>2003</u> | <u>2002</u> |
| Revenue | \$ 23,204 | \$ 21,556 | \$ 66,861 | \$ 62,972 |
| Net loss | \$ (1,161) | \$ (4,454) | \$ (6,366) | \$ (18,485) |
| Net loss per share – basic and diluted | \$ (0.03) | \$ (0.12) | \$ (0.17) | \$ (0.48) |

3. Revenue Recognition

As of September 30, 2003, there was \$1,144 of revenue earned on contracts in excess of billings, which is included in the balance of accounts receivable, and \$3,827 of billings in excess of revenue earned on contracts in progress, which is included in the balance of deferred revenue. Billings on contracts where revenue has been earned in excess of billings are expected to occur in accordance with the contract terms.

4. Comprehensive Loss

Comprehensive loss includes all changes in stockholders' equity during a period except those resulting from investments by owners and distributions to owners. Comprehensive loss for the three and nine months ended September 30, 2003 and 2002 consisted of the following:

| | <u>Three Months Ended September 30,</u> | | <u>Nine Months Ended September 30,</u> | |
|---|---|-------------------|--|--------------------|
| | <u>2003</u> | <u>2002</u> | <u>2003</u> | <u>2002</u> |
| Net loss | \$ (918) | \$ (3,199) | \$ (5,095) | \$ (13,185) |
| Other comprehensive income: | | | | |
| Unrealized gain (loss) on marketable Securities, net of taxes | (193) | 208 | (331) | 150 |
| Comprehensive loss | <u>\$ (1,111)</u> | <u>\$ (2,991)</u> | <u>\$ (5,426)</u> | <u>\$ (13,035)</u> |

5. Restructuring and Other Charges

In July 2001, Allscripts announced and began implementation of a restructuring plan to realign its organization; prioritize its initiatives around high-growth areas of its business; focus on profitability; reduce operating expenses; improve efficiencies in light of recent acquisitions; and focus sales and service efforts on larger physician practices, academic medical centers, and integrated delivery networks. The restructuring plan included workforce and overhead reduction and the termination of certain unprofitable strategic agreements and customer relationships. All charges discussed in the following paragraphs were recorded as operating expenses in the statement of operations, except \$2,201 recorded during 2001, which was classified as cost of revenue.

Restructuring

Workforce reduction

The restructuring plan contemplated the termination of 232 employees across all business functions, of which 231 were terminated as of September 30, 2003. As part of the restructuring charge, Allscripts recorded a workforce reduction charge in 2001 of \$3,317 consisting primarily of severance and related benefits, which will be paid out over time. During 2002, an additional charge of \$186 was recorded to satisfy the estimated remaining obligations as part of the workforce reduction.

Termination of agreements

Allscripts recorded a charge of \$1,053 in 2001 related to the termination of certain agreements and non-cancelable leases that were originally expected to increase product distribution and enhance product offerings. The charge includes estimated payments for the early termination of these agreements, all of which have been terminated, except the lease agreements, which will expire through January 2006.

Other Charges

Termination of unprofitable customer contracts

Allscripts recorded a charge in 2001 of \$4,266 related to the termination of unprofitable customer contracts where system utilization was low. The charge relates to the reduction of the carrying value of receivables to their expected realizable value and the costs for disposition of assets relating to these sites resulting from terminating the customer relationship.

Executive departure

Allscripts recorded a charge in 2002 of \$414 for severance costs in connection with the departure of the former chief financial officer.

A summary of the activity and balances of the accrued restructuring and other charges is outlined as follows:

| | Balance at December 31, 2002 | Cash Payments | Balance at September 30, 2003 |
|---------------------------|---------------------------------|---------------|----------------------------------|
| Restructuring | | | |
| Workforce reduction | \$ 479 | \$ 467 | \$ 12 |
| Termination of agreements | 311 | 300 | 11 |
| Subtotal | 790 | 767 | 23 |
| Other Charges | | | |
| Executive departure | 350 | 193 | 157 |
| Total | <u>\$ 1,140</u> | <u>\$ 960</u> | <u>\$ 180</u> |

6. Net Loss Per Share

Allscripts accounts for net loss per share in accordance with SFAS No. 128, "Earnings per Share," which requires the presentation of basic and diluted earnings per share. Basic loss per share is computed by dividing the net loss by the weighted average shares of outstanding common stock. For purposes of calculating diluted loss per share, the denominator includes both the weighted average shares of common stock and dilutive common stock equivalents.

In accordance with SFAS No. 128, basic and diluted net loss per share have been computed using the weighted average number of shares of common stock outstanding during the period. Allscripts has excluded the impact of all outstanding warrants and options to purchase shares of common stock because all such securities are antidilutive for all periods presented. Antidilutive potential common stock securities excluded from the diluted loss per share computation consisted of 10,843 and 8,075 options and 3 and 3 warrants at September 30, 2003 and 2002, respectively.

7. Business Segments

SFAS No. 131, "Disclosures about Segments of a Business Enterprise and Related Information," establishes standards for reporting information about operating segments in annual financial statements and requires selected information about operating segments in interim financial reports issued to stockholders. Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance.

Allscripts currently organizes its business around groups of similar products, which results in three reportable segments being reported: prepackaged medications; software and related services; and information services. The prepackaged medications segment derives its revenue from the repackaging, sale, and distribution of medications and medical supplies. The software and related services segment derives its revenue from the sale and service of software that provides point-of-care decision support solutions and the resale of related hardware. The information services segment primarily derives its revenue from the sale of interactive physician education sessions. Allscripts does not report its assets by segment. Allscripts does not allocate interest income, interest expense, other income or income taxes to its operating segments. Prior to 2003, Allscripts allocated all corporate operating expenses to its operating segments. In 2003, Allscripts discontinued its practice of allocating all corporate operating expenses to its operating segments. Accordingly, 2002 segment results have been restated to reflect the 2003 presentation.

| | For the Three Months Ended September 30, | | For the Nine Months Ended September 30, | |
|--------------------------------|---|-------------------|--|--------------------|
| | 2003 | 2002 | 2003 | 2002 |
| Revenue: | | | | |
| Prepackaged medications | \$ 10,990 | \$ 12,799 | \$ 34,278 | \$ 37,758 |
| Software and related services | 8,232 | 4,819 | 20,048 | 14,276 |
| Information services | 3,266 | 2,388 | 7,862 | 6,839 |
| Total revenue | <u>\$ 22,488</u> | <u>\$ 20,006</u> | <u>\$ 62,188</u> | <u>\$ 58,873</u> |
| Profit (loss) from operations: | | | | |
| Prepackaged medications | \$ 1,858 | \$ 2,142 | \$ 6,027 | \$ 5,900 |
| Software and related services | (623) | (2,118) | (4,100) | (9,855) |
| Information services | 1,072 | 564 | 2,463 | 1,933 |
| Unallocated corporate expenses | (3,565) | (4,401) | (10,567) | (13,273) |
| Loss from operations | (1,258) | (3,813) | (6,177) | (15,295) |
| Net interest and other income | 340 | 614 | 1,082 | 2,110 |
| Loss before income taxes | <u>\$ (918)</u> | <u>\$ (3,199)</u> | <u>\$ (5,095)</u> | <u>\$ (13,185)</u> |

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

(Dollar amounts in thousands)

Overview

Allscripts Healthcare Solutions is a leading provider of clinical software and information solutions for physicians. Our key offerings fall into three business segments. Our software and services segment is comprised primarily of our TouchWorksTM software business. TouchWorks is a modular electronic medical record (*mEMR*TM) designed to enhance physician productivity using a wireless handheld device, Tablet PC, or desktop workstation to automate the most common physician activities. Our information services segment is comprised primarily of our Physicians InteractiveTM (PI) business. PI links physicians with pharmaceutical companies and medical suppliers using interactive education sessions to provide product information to the physician. Finally, our prepackaged medications segment is comprised of our Allscripts DirectTM business. Allscripts Direct provides point-of-care medication, and medical supply management solutions for physicians.

On August 1, 2003, Allscripts acquired Advanced Imaging Concepts, Inc. (AIC), a leading provider of document imaging, scanning and management software for healthcare providers. Pursuant to the agreement, Allscripts acquired all outstanding shares of AIC common stock and common stock equivalents for \$18,000, payable in cash and by the assumption of a portion of outstanding AIC stock options. AIC has become part of our software and services segment.

On August 8, 2003, Allscripts acquired certain assets of RxCentric Inc., a leading provider of technology-enabled sales and marketing solutions for the pharmaceutical industry. Pursuant to the agreement, Allscripts acquired substantially all of the assets of RxCentric for \$4,500 in cash and assumed liabilities and additional contingent consideration of up to \$1,750 if certain performance targets are met during the year following the close. The acquired assets and related activities have been fully integrated into our Physicians Interactive business. Thus, revenue and related expenses from the acquired assets of RxCentric will be reported as part of the information services segment.

We provide three key product and service offerings, each of which focuses on the physician. Allscripts Direct provides medication management solutions for physicians. TouchWorks and AIC provide software that automates the most common physician activities. Physicians Interactive provides interactive educational opportunities for the physician. We believe that TouchWorks, AIC and Physicians Interactive represent our largest potential for growth.

We currently organize our business around the three aforementioned segments: prepackaged medications; software and related services; and information services. The prepackaged medications segment derives its revenue from the repackaging, sale, and distribution of medications and medical supplies. The software and related services segment derives its revenue from the sale and service of software that provides point-of-care decision support solutions and the resale of related hardware. The information services segment primarily derives its revenue from the sale of interactive physician education sessions.

The composition of our revenue is as follows (unaudited) for the quarter ended:

| | 2002 | | | | 2003 | | |
|-------------------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| | March 31, | June 30, | Sept. 30, | Dec. 31, | March 31, | June 30, | Sept. 30, |
| Prepackaged medications | \$ 12,479 | \$ 12,480 | \$ 12,799 | \$ 11,540 | \$ 12,118 | \$ 11,170 | \$ 10,990 |
| Software and related services | 4,439 | 5,018 | 4,819 | 5,645 | 5,796 | 6,020 | 8,232 |
| Information services | 1,855 | 2,596 | 2,388 | 2,744 | 2,116 | 2,480 | 3,266 |
| Total revenue | <u>\$ 18,773</u> | <u>\$ 20,094</u> | <u>\$ 20,006</u> | <u>\$ 19,929</u> | <u>\$ 20,030</u> | <u>\$ 19,670</u> | <u>\$ 22,488</u> |

Cost of revenue for the prepackaged medications segment consists primarily of the cost of the prepackaged medications, the salaries, bonuses and benefits for the repackaging personnel, shipping costs, repackaging facility and other costs. Cost of revenue for the software and related services segment consists primarily of the salaries, bonuses and benefits of our billable professionals, third party software costs, hardware cost, capitalized software amortization and other direct engagement costs. Cost of revenue for the information services segment consists primarily of salaries, bonuses and benefits of our program management and program development personnel, costs to recruit physicians and other program management costs.

Selling, general and administrative expenses consist primarily of salaries, bonuses and benefits for management and support personnel, facilities costs, depreciation and amortization, general operating expenses, non-capitalized product development expenses, and selling and marketing expenses. Selling, general and administrative expenses for each segment consist of expenses directly related to that segment.

Three and Nine Months Ended September 30, 2003 Compared to Three and Nine Months Ended September 30, 2002

Prepackaged Medications

Prepackaged medications revenue decreased by 14.1%, or \$1,809, from \$12,799 for the three months ended September 30, 2002 to \$10,990 for the same period in 2003. Prepackaged medications revenue decreased by 9.2%, or \$3,480, from \$37,758 for the nine months ended September 30, 2002 to \$34,278 for the same period in 2003. The decrease in both periods reflects a decrease in the volume of prepackaged medications sold related to the termination of several less-profitable customer relationships, the bankruptcy of a large customer, and lower revenue from occupational health customers, which tend to be more sensitive to general economic trends.

Gross profit for prepackaged medications for the three months ended September 30, 2003 decreased by 9.5%, or \$242, from \$2,542 in 2002 to \$2,300 in 2003. Gross profit for prepackaged medications for the nine months ended September 30, 2003 increased by 3.7%, or \$264, from \$7,171 in 2002 to \$7,435 in 2003. Gross profit as a percentage of revenue for the three months ended September 30, 2003 was 20.9% compared with 19.9% for the same period in 2002. Gross profit as a percentage of revenue for the nine months ended September 30, 2003 was 21.7% compared with 19.0% for the same period in 2002. The decrease in gross profit for the three months ended September 30, 2003 was primarily due to a decrease in overall revenue for the segment, partially offset by more favorable buying arrangements with suppliers as well as the elimination of less-profitable customer relationships. The increase in gross profit for the first nine months of 2003 and gross profit as a percentage of revenue in all periods was primarily due to more favorable buying arrangements with suppliers as well as the elimination of less-profitable customer relationships.

Operating expenses for prepackaged medications for the three months ended September 30, 2003 increased by 10.5%, or \$42, from \$400 in 2002 to \$442 in 2003. Operating expenses for prepackaged medications for the nine months ended September 30, 2003 increased by 10.8%, or \$137, from \$1,271 in 2002 to \$1,408 in 2003. The increase in both periods was primarily due to increased sales and service expenditures.

Software and Related Services

Software and related services revenue for the three months ended September 30, 2003 increased by 70.8%, or \$3,413, from \$4,819 in 2002 to \$8,232 in 2003. Software and related services revenue for the nine months ended September 30, 2003 increased by 40.4%, or \$5,772, from \$14,276 in 2002 to \$20,048 in 2003. The increases reflect an increase in the implementation of our integrated content and clinical workflow products and the inclusion of revenue from AIC, which was acquired in August 2003.

Gross profit for software and related services increased by 214.4%, or \$3,004, from \$1,401 in the third quarter of 2002 to \$4,405 in the third quarter of 2003. Gross profit for software and related services increased by 233.3%, or \$6,483, from \$2,779 in the first nine months of 2002 to \$9,262 in the same period of 2003. Gross profit as a percentage of revenue increased to 53.5% in the third quarter of 2003 from 29.1% in the same period in 2002. Gross profit as a percentage of revenue increased to 46.2% in the first nine months of 2003 from 19.5% in the same period in 2002. The increase in both gross profit and gross profit as a percentage of revenue resulted from the increase in revenue combined with the simultaneous reduction of our costs of implementation, training, and support by realizing improved efficiencies in those processes, as well as the addition of the AIC product line, which tends to have higher associated gross margins.

Operating expenses for software and related services for the three months ended September 30, 2003 increased by 42.9%, or \$1,509, from \$3,519 in 2002 to \$5,028 in 2003. The increase in operating expenses was primarily the result of higher marketing expenditures in 2003 as compared to 2002, as more of the 2002 expenses were offset by vendor sponsorships, as well as the addition of operating expenses from AIC. In addition, during the three months ended September 30, 2003, we capitalized \$478 of software development costs in accordance with Statement of Financial Accounting Standards (SFAS) No. 86, "Accounting for the Costs of Computer Software to Be Sold, Leased, or Otherwise Marketed," compared to \$1,069 during the same period in 2002.

Operating expenses for software and related services for the nine months ended September 30, 2003 increased by 5.8%, or \$728, from \$12,634 in 2002 to \$13,362 in 2003. The increase in operating expenses was primarily the result of higher marketing expenditures in 2003 as compared to 2002, as more of the 2002 expenses were offset by vendor sponsorships, as well as the addition of operating expenses from AIC, partially offset by lower costs as a result of workforce reductions that took place in the first half of 2002 aimed at improving efficiencies in light of acquisitions made during 2001 and 2000, and our decision to focus sales and service efforts on larger physician practices. During the nine months ended September 30, 2003 and 2002, we capitalized \$1,134 and \$1,813, respectively, of software development costs pursuant to SFAS No. 86.

Information Services

Information services revenue increased by 36.8%, or \$878, from \$2,388 in the third quarter of 2002 to \$3,266 in 2003. Information services revenue increased by 15.0%, or \$1,023, from \$6,839 in the first nine months of 2002 to \$7,862 in 2003. The increase in information services revenue in both periods reflects an increase in the number of interactive physician education programs sold and completed, as well as the addition of revenue from our RxCentric acquisition, which closed in August 2003.

Gross profit for information services for the three months ended September 30, 2003 increased 50.8%, or \$657, from \$1,293 in 2002 to \$1,950 in 2003. Gross profit for information services for the nine months ended September 30, 2003 increased 14.3%, or \$585, from \$4,078 in 2002 to \$4,663 in 2003. Gross profit as a percentage of revenue increased to 59.7% for the third quarter of 2003 from 54.1% in the same period in 2002. Gross profit as a percentage of revenue decreased to 59.3% for the first nine months of 2003 from 59.6% in the same period in 2002. The increases in gross profit in both periods and gross profit as a percentage of revenue in the third quarter of 2003 were primarily due to an increase in revenue in 2003.

Operating expenses for information services for the three months ended September 30, 2003 increased by 20.4%, or \$149, from \$729 in 2002 to \$878 in 2003. Operating expenses for information services for the nine months ended September 30, 2003 increased by 2.6%, or \$55, from \$2,145 in 2002 to \$2,200 in 2003. The increase in the third quarter of 2003 was primarily due to the addition of expenses from our RxCentric acquisition. The increase in the first nine months of 2003 was due to the addition of expenses from our RxCentric acquisition, offset by reduced marketing efforts in emerging markets.

Unallocated Corporate Expenses

Unallocated corporate expenses for the three months ended September 30, 2003 decreased by 19.0%, or \$836, from \$4,401 in 2002 to \$3,565 in 2003. Unallocated corporate expenses for the nine months ended September 30, 2003 decreased by 20.4%, or \$2,706, from \$13,273 in 2002 to \$10,567 in 2003. During the third quarter of 2002, we recorded a charge of \$600 related to executive severance and the remaining obligation under our restructuring that began in 2001. The remainder of the decrease in the third quarter of 2003 was primarily the result of lower headcount in 2003 when compared to 2002 and a lower provision for doubtful accounts in 2003 due to a decrease in overall accounts receivable balance. The remainder of the decrease in the first nine months of 2003 was a result of lower headcount in 2003 when compared to 2002, lower facility-related costs in 2003, and a lower provision for doubtful accounts in 2003 due to a decrease in overall accounts receivable.

Interest and Other Income

Interest and other income for the three months ended September 30, 2003 was \$340 as compared to \$614 for the same period in the prior year. Interest and other income for the nine months ended September 30, 2003 was \$1,082 as compared to \$2,110 for the same period in the prior year. The decrease is primarily due to lower interest income related to a lower average cash and marketable securities balance and a decrease in the average interest rates earned on our investments during 2003.

Liquidity and Capital Resources

At September 30, 2003, our principal sources of liquidity consisted of \$10,496 of cash and cash equivalents and \$41,702 of marketable securities for a total of \$52,198 in cash, cash equivalents and marketable securities. At September 30, 2003, we had working capital of \$16,299 and an accumulated deficit of \$558,634.

Net cash provided by operating activities was \$3,886 for the nine months ended September 30, 2003. The net loss for the first nine months of 2003 was \$5,095, which was partially offset by non-cash charges of \$4,300. Accounts receivable decreased by \$3,412 during the nine months ended September 30, 2003, due to strong collections. Accounts payable increased by \$2,241 during the nine months ended September 30, 2003, as a result of timing related to payments to large suppliers and leveraging favorable payment terms. Accrued compensation decreased by \$1,040 during the nine months ended September 30, 2003, primarily as a result of the payment of 2002 annual compensation commitments. All other operating activities contributed \$68 to the cash provided by operations.

Net cash used in investing activities was \$10,672 for the nine months ended September 30, 2003. Cash used in investing activities resulted primarily from net payments for the aforementioned acquisitions of AIC and the assets of RxCentric of \$14,977, offset by net maturities of marketable securities of \$6,035. In addition, we capitalized software and website development costs of \$1,205. Also, capital expenditures were \$525 for the nine months ended September 30, 2003 as a result of capital outlays to support the future growth of our business. Currently, we have no material commitments for capital expenditures, although we anticipate ongoing capital expenditures in the range of \$250 to \$500 per quarter in the ordinary course of business.

We expect to pay approximately \$400 in the fourth quarter of 2003 to complete the RxCentric acquisition. We expect to pay approximately \$700 in the fourth quarter of 2003 and \$1,800 in first quarter of 2005 to complete the AIC acquisition.

The following table summarizes our contractual obligations at September 30, 2003, and the effect such obligations are expected to have on our liquidity and cash in future periods:

| | Total | Remainder of 2003 | 2004 – 2005 | 2006-2007 | 2008+ |
|--------------------------------------|-----------------|----------------------|-----------------|-----------------|-----------------|
| Contractual obligations: | | | | | |
| Non-cancelable capital leases | \$ 41 | \$ 7 | \$ 32 | \$ 2 | \$ — |
| Non-cancelable operating leases | 6,291 | 324 | 2,591 | 2,061 | 1,315 |
| Acquisition payment obligations | 2,938 | 1,138 | 1,800 | — | — |
| Total contractual obligations | \$ 9,270 | \$ 1,469 | \$ 4,423 | \$ 2,063 | \$ 1,315 |

We believe that our existing cash and cash equivalents and marketable securities will be sufficient to meet the anticipated cash needs of our current business for at least the next twelve months. However, any projections of future cash needs and cash flows are subject to substantial uncertainty. We will, from time to time, consider the acquisition of, or investment in, complementary businesses, products, services and technologies, which might impact our liquidity requirements or cause us to issue additional equity or debt securities. There can be no assurance that financing will be available in the amounts or on terms acceptable to us, if at all.

A full discussion of all critical accounting policies is included in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of our Annual Report on Form 10-K for the year ended December 31, 2002.

Recent Accounting Pronouncements

In May 2003, the Emerging Issues Task Force of the Financial Accounting Standards Board reached a consensus on Issue 00-21, “Revenue Arrangements with Multiple Deliverables.” The consensus sets revenue recognition guidance for arrangements that have multiple deliverables. The consensus is effective for arrangements entered into in fiscal periods beginning after June 15, 2003. We have adopted the consensus and the adoption had no material impact on our consolidated financial position or results of operation.

Safe Harbor For Forward-Looking Statements

This report, including “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Notes to Consolidated Financial Statements,” and statements we or our representatives make may contain forward-looking statements that involve risks and uncertainties. We develop forward-looking statements by combining currently available information with our beliefs and assumptions. These statements often contain words like believe, expect, anticipate, intend, contemplate, seek, plan, estimate or similar expressions. Forward-looking statements do not guarantee future performance. Recognize these statements for what they are and do not rely upon them as facts.

Forward-looking statements involve risks, uncertainties and assumptions, including, but not limited to, those discussed in this report. We make these statements under the protection afforded them by Section 21E of the Securities Exchange Act of 1934. Because we cannot predict all of the risks and uncertainties that may affect us, or control the ones we do predict, our actual results may be materially different from the results we express in our forward-looking statements. Unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For a more complete discussion of the risks, uncertainties and assumptions that may affect us, see the “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2002.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As of September 30, 2003, we did not own any derivative instruments, but we were exposed to market risks, primarily due to changes in U.S. interest rates. As of September 30, 2003, we had cash, cash equivalents and marketable securities in financial instruments of \$52,198. Maturities average less than two years. Declines in interest rates over time will reduce our interest income from our investments. Based upon our balance of cash, cash equivalents and marketable securities as of September 30, 2003, a decrease in interest rates of 1.0% would cause a corresponding decrease in our annual interest income of approximately \$522.

Item 4. Controls and Procedures

As of September 30, 2003, our management, including our Chief Executive Officer and Chief Financial Officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15(b). Based on their review and evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures are adequate and effective.

In connection with the evaluation by management, including our Chief Executive Officer and Chief Financial Officer, pursuant to Exchange Act Rule 13a-15(d), no changes during the quarter ended September 30, 2003 were identified that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K.

(a) **Exhibits**—See Index to Exhibits.

(b) **Reports on Form 8-K.**

On July 16, 2003, we furnished a report on Form 8-K under Items 9 and 12 in connection with the announcement of our second quarter 2003 earnings.

On July 16, 2003, we filed a report on Form 8-K under Item 5 in connection with the announcement of acquisitions agreements with Advanced Imaging Concepts, Inc. and RxCentric Inc.

On August 8, 2003, we filed a report on Form 8-K under Items 2 and 7 in connection with the acquisition of Advanced Imaging Concepts, Inc.

On August 14, 2003, we filed a report on Form 8-K under Items 2 and 7 in connection with the acquisition of certain assets of RxCentric Inc.

On September 19, 2003, we filed a report on Form 8-K/A-1 under Item 7 amending the date we would provide financial statements in connection with the acquisition of certain assets of RxCentric Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
(Registrant)

By: _____
/s/ William J. Davis
William J. Davis
Chief Financial Officer
(Duly Authorized Officer and
Principal Financial Officer)

Date: November 14, 2003

Index to Exhibits

| Exhibit Number | Description | References |
|----------------|---|--|
| 2.1 | Agreement and Plan of Merger, dated as of March 13, 2000, among Allscripts, Inc., MC Acquisition Corp., MasterChart, Inc. and certain shareholders of MasterChart, Inc., together with a list of exhibits and schedules thereto. Such exhibits and schedules are not filed, but the Registrant undertakes to furnish a copy of any such exhibit or schedule to the Securities and Exchange Commission upon request. | Incorporated herein by reference from the Allscripts, Inc. Current Report on Form 8-K filed on May 24, 2000, as amended on July 24, 2000 and July 25, 2000 |
| 2.2 | Amendment No. 1 to Agreement and Plan of Merger, dated as of May 9, 2000, by and among Allscripts Inc., MC Acquisition Corp., MasterChart, Inc. and certain shareholders of MasterChart, Inc. | Incorporated herein by reference from the Allscripts, Inc. Current Report on Form 8-K filed on May 24, 2000, as amended on July 24, 2000 and July 25, 2000 |
| 2.3 | Agreement and Plan of Merger, dated as of April 12, 2000, among Allscripts, Inc., WebDoc Acquisition Corp., Medifor, Inc. and certain shareholders of Medifor, Inc., together with a list of exhibits and schedules thereto. Such exhibits and schedules are not filed, but the Registrant undertakes to furnish a copy of any such exhibit or schedule to the Securities and Exchange Commission upon request. | Incorporated herein by reference from the Allscripts, Inc. Current Report on Form 8-K filed on May 31, 2000, as amended on July 25, 2000 |
| 2.4 | Agreement and Plan of Merger, dated as of July 13, 2000, by and among Allscripts Holding, Inc., Allscripts, Inc., Bursar Acquisition, Inc., Bursar Acquisition No. 2, Inc., IDX Systems Corporation and Channelhealth Incorporated. | Incorporated herein by reference from the Allscripts, Inc. Current Report on Form 8-K filed on July 27, 2000 |
| 2.5 | First Amendment to Agreement and Plan of Merger, entered into as of November 29, 2000, by and among Allscripts Holding, Inc., Allscripts, Inc., Bursar Acquisition, Inc., Bursar Acquisition No. 2, Inc., IDX Systems Corporation and Channelhealth Incorporated. | Incorporated herein by reference from the Allscripts Healthcare Solutions, Inc. Registration Statement on Form S-4 as part of Amendment No. 1 filed on December 7, 2000 (SEC file no. 333-49568) |
| 2.6 | Merger Agreement dated as of July 16, 2003 by and among Allscripts Healthcare Solutions, Inc., Image Acquisition Corp., Advanced Imaging Concepts, Inc. and bCatalyst LLC, including the First Amendment thereto. | Incorporated herein by reference from the Allscripts Healthcare Solutions, Inc. Current Report on Form 8-K filed on August 8, 2003 |
| 2.7 | Asset Purchase Agreement, dated as of July 16, 2003, as amended, by and between Allscripts, LLC and RxCentric Inc. | Incorporated herein by reference from the Allscripts Healthcare Solutions, Inc. Current Report on Form 8-K filed on August 14, 2003 |
| 3.1 | Amended and Restated Certificate of Incorporation of Allscripts Healthcare Solutions, Inc. (formerly named Allscripts Holding, Inc.). | Incorporated herein by reference from the Allscripts Healthcare Solutions, Inc. Registration Statement on Form S-4 as part of Amendment No. 1 filed on December 7, 2000 (SEC file no. 333-49568) |
| 3.2 | Certificate of Amendment of Amended and Restated Certificate of Incorporation of Allscripts Healthcare Solutions, Inc. (formerly named Allscripts Holding, Inc.). | Incorporated herein by reference from the Allscripts Healthcare Solutions, Inc. Registration Statement on Form S-4 as part of Amendment No. 1 filed on December 7, 2000 (SEC file no. 333-49568) |
| 3.3 | Certificate of Amendment of Amended and Restated Certificate of Incorporation of Allscripts Healthcare Solutions, Inc. (formerly named Allscripts Holding, Inc.). | Incorporated herein by reference from the Allscripts Healthcare Solutions, Inc. Registration Statement on Form S-4 as part of Amendment No. 1 filed on December 7, 2000 (SEC file no. 333-49568) |
| 3.4 | Bylaws of Allscripts Healthcare Solutions, Inc. (formerly named Allscripts Holding, Inc.). | Incorporated herein by reference from the Allscripts Healthcare Solutions, Inc. Registration Statement on Form S-4 as part of Amendment No. 1 filed on December 7, 2000 (SEC file no. 333-49568) |

| Exhibit Number | Description | References |
|---------------------------|--|-------------------|
| 31.1 | Rule 13a-14(a) Certifications of Chief Executive Officer and Chief Financial Officer | |
| 32.1 | Section 1350 Certifications of Chief Executive Officer and Chief Financial Officer | |

Certification

I, Glen E. Tullman, certify that:

1. I have reviewed this report on Form 10-Q of Allscripts Healthcare Solutions, Inc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:
 - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
 - c. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2003

/s/ Glen E. Tullman
Chairman and Chief Executive Officer

Certification

I, William J. Davis, certify that:

1. I have reviewed this report on Form 10-Q of Allscripts Healthcare Solutions, Inc;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:
 - a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and
 - c. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting;
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2003

/s/ William J. Davis
Chief Financial Officer

The following statement is being made to the Securities and Exchange Commission solely for purposes of Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), which carries with it certain criminal penalties in the event of a knowing or willful misrepresentation.

Securities and Exchange Commission
450 Fifth Street, NW
Washington, DC 20549

Re: Allscripts Healthcare Solutions, Inc.

Ladies and Gentlemen:

In accordance with the requirements of Section 906 of the Sarbanes-Oxley Act of 2002 (18 USC 1350), each of the undersigned hereby certifies that:

(i) this Quarterly Report on Form 10-Q fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(ii) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Allscripts Healthcare Solutions, Inc.

Dated as of this 14th day of November, 2003.

/s/ Glen E. Tullman
Glen E. Tullman
Chairman and Chief Executive Officer

/s/ William J. Davis
William J. Davis
Chief Financial Officer
